Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

A former Boone County bean field is where Lilly will research, develop, and manufacture the medicines of the future. Company ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...

Lilly's weekly prescription data for Zepbound is up 354% year-over-year, while Novo's Wegovy is up just 61%. That's based on ...

Eli Lilly and Company became the first tenant to move into Lebanon’s LEAP district during a groundbreaking ceremony on ...

Eli Lilly is set to report Q1 earnings on May 1. Analysts predict strong growth, but margin pressures and guidance revisions ...

UBS has adjusted its outlook on Eli Lilly and Company (NYSE: LLY), reducing its stock price target to $1,050 while maintaining a Buy rating. This move ...